Elranatamab for treating hemophilia A with inhibitors
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new drug, elranatamab, to see if it can eliminate factor VIII inhibitors in people with hemophilia A. Participants receive the drug and are monitored for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hemophilia A with factor VIII level less than 2%.
- You must have a factor VIII inhibitor that has been detected twice and is currently above 10 Bethesda units.
- You must be between 18 and 65 years old.
- You must not have other autoimmune diseases, recent cancer, or serious infections.
- You must have normal kidney and liver function tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Hear when a new Hemophilia A With Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.